Phase 2 study of bevacizumab and irinotecan as second-line therapy in patients with advanced colorectal cancer previously treated with oxaliplatin and bavacizumab

Interventions: Bevacizumab+Irinotecan Bevacizumab: 10mg/kg d.i.v. day1 Irinotecan:150mg/m2 d.i.v.day1 to be repeated every 2 weeks
Primary outcome(s): Progression free survival
Study Design: Single arm Non-randomized

干预措施：贝伐珠单抗（Bevacizumab）联合伊立替康（Irinotecan），具体给药方案为：贝伐珠单抗10mg/kg，d.i.v.，第1天；伊立替康150mg/m²，d.i.v.，第1天，每2周重复给药。
主要终点：无进展生存期（Progression Free Survival）。
试验设计：单臂非随机试验。